Key facts
- This page summarizes James E. Levine's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Mar 2022, 17:40.
James E. Levine - 09 Mar 2022 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CRDF
- Reported as of
- 09 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Mar 2022, 17:40:57 UTC
- Prior SEC filing
- 13 Sep 2021
- Next SEC filing
- 19 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Levine
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James E. Levine filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 10 Mar 2022.
Change
- Previous filing in this sequence was filed on 13 Sep 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRDF
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +170,016
- Change %
- +44%
- Price
- $0.000000
- Shares after
- 560,016
- Date
- 09 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 170,016
- Exercise price
- $2.50
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
42,504 vest on 3/09/2023. 3,542 vest monthly for 36 months beginning on 4/09/2023 through 3/09/2026.